ASH 2014: Mixed results for PD-1, CAR-T in blood cancers

The 56th American Society of Hematology (ASH) Annual Meeting and Exposition from 6 to 9 December in San Francisco will give immunotherapy developers a chance to present efficacy (or lack thereof) in hematological malignancies after a fairly strong showing at this summer's American Society of Clinical Oncology (ASCO) conference (scripintelligence.com, 5 June 2014).

The 56th American Society of Hematology (ASH) Annual Meeting and Exposition from 6 to 9 December in San Francisco will give immunotherapy developers a chance to present efficacy (or lack thereof) in hematological malignancies after a fairly strong showing at this summer's American Society of Clinical Oncology (ASCO) conference (scripintelligence.com, 5 June 2014).

Abstracts for programmed cell death-1 (PD-1) inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies became public on 6 November, giving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas